SERUM GALACTOMANNAN ASPERGILLUS ANTIGEN TEST

In individuals with prolonged neutropenia or intense immunosuppressive treatments, Hypro Diagnostics addresses the challenges of diagnosing invasive aspergillosis (IA), which has an incidence of 5% to 20% and a mortality rate of 50% to 80%. Unfortunately, around 30% of cases remain undiagnosed until death. The diagnostic process, complicated by patient criticality, typically relies on histopathological evidence or positive cultures, which have low sensitivity. A recent breakthrough is the FDA-approved serologic assay for detecting galactomannan, allowing earlier detection and preemptive antifungal therapy initiation. Positive results support an IA diagnosis, considered with other methods. A negative result doesn’t exclude IA, prompting repeat testing if suspicion persists. Regular monitoring is crucial, and galactomannan levels indicate therapeutic response, decreasing with effective antimicrobial therapy. Hypro Diagnostics is dedicated to addressing the complexities of IA diagnosis and intervention.